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Summary 
The ATR-X syndrome is an X-linked disorder compris- 
ing severe psychomotor retardation, characteristic fa- 
cial features, genital abnormalities, and a-thalasse- 
mia. We have shown that ATR-X results from diverse 
mutations of XH2, a member of a subgroup of the hell- 
case superfamily that includes proteins involved in a 
wide range of cellular functions, including DNA recom- 
bination and repair (RAD16, RAD54, and ERCC6) and 
regulation of transcription (SWl2/SNF2, MOT1, and 
brahma). The complex ATR-X phenotype suggests 
that XH2, when mutated, down-regulates expression 
of several genes, including the a-globin genes, indicat- 
ing that it could be a global transcriptional regulator. 
In addition to its role in the ATR-X syndrome, XH2 may 
be a good candidate for other forms of X-linked mental 
retardation mapping to Xq13. 
Introduction 
X-linked mental retardation (XLMR) occurs at a frequency 
of between 1.8 and 3.4 per 1000 individuals and includes 
at least 50 distinct syndromes (Neri et al., 1994). Together 
these represent he most frequent causes of mental retar- 
dation in males, and some forms of XLMR provide a signifi- 
cant contribution to mental handicap in manifesting female 
carriers. The ATR-X syndrome is a severe, nonprogressive 
type of XLMR characterized by its association with an un- 
usual form of ~z-thalassemia that can be readily detected 
by demonstrating hemoglobin H (134) inclusions in the pe- 
ripheral red blood cells (Weatherall et al., 1981, cases 2 
and 3; Wilkie et al., 1990; Gibbons et al., 1995). Affected 
boys have a typical facial appearance, genital abnormali- 
ties, severe psychomotor etardation, and a wide range 
of minor congenital abnormalities. Carrier females may 
have very mild hematologic changes but are otherwise 
normal. Previous studies localized the ATR-X syndrome 
to an interval of approximately 11 cM between DXSI06 
and DXYSIX (Xq12-q21.31) with a peak Iod score of 5.42 
(DXS72) (Gibbons et al., 1992); a significant proportion of 
all XLMR maps to this region (Neri et al., 1994). 
We have previously suggested that the remarkably con- 
sistent core of clinical findings in boys with the ATR-X 
syndrome indicates that the molecular defect probably in- 
volves a single gene rather than a group of contiguous 
genes (Gibbons et al., 1995). The wide spectrum of tissues 
and systems affected, however, suggests that the muta- 
tions within such a gene exert pleiotropic effects through- 
out development. In this respect, it is of interest hat female 
carriers have a remarkably skewed (greater than 20:1) 
pattern of X inactivation i  tissues representing mesoderm 
(blood), endoderm (buccal mucosa), and ectoderm (hair 
root), consistent with a strong selective disadvantage con- 
ferred by the mutated gene (Gibbons et al., 1992). 
The invariable occurrence of a-thalassemia in this syn- 
drome suggests that the X-linked gene encodes a protein 
that, when mutated, down-regulates expression of the 
structurally normal ~-globin genes (on chromosome 16) 
in addition to modifying expression of other (as yet uniden- 
tified) genes. Expression of the ~-globin genes has been 
extensively studied: the critical cis-acting regulatory se- 
quences have been defined, and some of the proteins that 
interact with them have been identified (Higgs et al., 1990; 
Jarman et al., 1991). In the ATR-X syndrome, we have 
previously shown that although all of these cis-acting regu- 
latory sequences are intact and retain their normal pat- 
terns of methylation, the levels of a-globin mRNA and 
~-globin chain synthesis are reduced to 30%-65% of nor- 
mal (Wilkie et al., 1990). Analysis of a-globin gene expres- 
sion in this syndrome may thus provide an opportunity to 
elucidate the mechanism(s) by which mutation of a trans- 
acting factor could perturb the function of target genes 
with widely differing roles. 
To refine the localization of the disease gene responsi- 
ble for the ATR-X syndrome, we have performed linkage 
analysis in nine further families and identified key recombi- 
nants that reduce the area of interest o 1.4 cM (estimated 
to be 15 Mb) between DXS453 and DXS72, within Xq13.1- 
q21.1. Recently, several cDNAs from this area have been 
isolated, and therefore we have examined these genes 
as candidates for the ATR-X syndrome. We have further 
characterized one of these cDNAs, which encodes a gene 
of the SNF2 family of putative helicases, and identified 
two premature in-phase stop mutations, seven missense 
mutations, and a small deletion that severely down- 
regulates (to <1%) expression of this gene in ATR-X pa- 
tients. 
Results 
Refining the Localization of ATR-X 
by Linkage Analysis 
Previous linkage analysis (Gibbons et al., 1992) in seven 
pedigrees localized the ATR-X locus to the proximal region 
of Xq (Xq12-q21.31). In this study we examined a further 
Cell 
838 
12 
13.1 
13.2 
Xq t33 
21.1 
21.2 
21.31 
AR 
DXSI06 
DXS453 
XIST 
DXS56 
tXH2 
MNK PGK1 
DXS72 
DXYS1X 
ATR-X 
Figure 1. Localization ofthe ATR-X Locus 
The order and cytogenetic positions of loci referred to in the text are 
shown: the right-hand column refers to markers used for haplotype 
analysis; the left-hand column refers to other markers of relevance. 
An arrow shows the direction of transcription ofXH2. Details of loci 
and probes are available from the Genome Data Base. 
nine families (ATR-X pedigree numbers 12, 14, 17, 20, 
21, 22, 23, 24, and 25). These and all other pedigrees 
used in this study are summarized in Gibbons et al. (1995). 
Using data from all 16 families, two-point Iod scores were 
calculated for 0s between the ATR-X locus and five pre- 
viously ordered polymorphic loci (Figure 1; Table 1). A 
peak Iod score of 9.56 at 0 = 0 was seen at PGK1. DXS453 
and DXS72 are the closest flanking markers that demon- 
strate recombination with the ATR-X locus. These loci lie 
approximately 1.4 cM apart (Wang et al., 1994) within the 
region Xq13.1-q21.1 and thus refine the localization of 
ATR-X to this segment of the X chromosome (Figure 1). 
A Search for Mutations of ATR-X 
High resolution cytogenetic analysis of all ATR-X patients 
studied to date has revealed no abnormality (Gibbons et 
al., 1995). Since this area of the genome has been well 
characterized (Schlessinger et al., 1993), we examined 
the X chromosome of up to 26 affected boys from unrelated 
families by the use of polymerase chain reaction (PCR), 
pulsed field gel electrophoresis, or conventional Southern 
blot hybridization using 29 previously described markers 
distributed across this region (data not shown). Using this 
approach we found no evidence for allele loss or genomic 
rearrangement. In a further attempt o identify mutations, 
we used previously described cDNAs (DXSlOO5E and 
DXS1103E) and six partial cDNA fragments (clones 23.1, 
J15, J14, Eg, E4, and E13) that had been isolated by direct 
cDNA selection (Gecz et al., 1993; L. V. et al., unpublished 
data) using total yeast artificial chromosome (YAC) DNA 
from within the candidate region. Using the 84 bp cDNA 
fragment (E4) isolated with YAC4551 (which includes the 
marker DXS56; Figure 1), we noted an absent hybridiza- 
tion signal in one individual (26.3; proband in McPherson 
et al., 1995) out of 26 ATR-X patients (Figure 2a). This 
same band was also shown to be missing from 26.3 (data 
not shown) when the panel of DNA samples was re- 
screened with the probe XNP3/4 (1000 bp) obtained by 
reverse transcriptase (RT)-PCR of cDNA corresponding 
to the 3' end of a previously described gene that had been 
localized to this region (Gecz et al., 1994; Stayton et al., 
1994). 
Characterization of cDNAs Corresponding 
to E4 and XNP3/4 
Since both E4 and part of XNP3/4 were shown to be miss- 
ing in patient 26.3, it seemed possible that they originated 
from the same gene. Northern blot analysis using RNA 
from Epstein-Barr virus (EBV)-transformed lymphoblasts 
from normal individuals howed that both probes identified 
indistinguishable, widely expressed 9.5 kb mRNA tran- 
scripts (data not shown), and subsequent sequence analy- 
sis (see below) confirmed that E4 lies entirely within 
XNP3/4. 
To allow further characterization of this gene in ATR-X 
patients, we used XNP3/4 and E4 to isolate a set of overlap- 
ping cDNA clones from human fetal brain and human heart 
cDNA libraries (Figure 3b). We also generated and cloned 
cDNA fragments by RT-PCR of cDNA derived from a nor- 
mal EBV-transformed lymphoblastoid cell line, using the 
previously described primers XNP3, XNP4, XNP7, and 
XNP8 or their reverse complements (Gecz et al., 1994). 
These clones, which mapped back to YAC4551 (data not 
shown), were then sequenced. Subsequent analysis dem- 
onstrated that the clones we had characterized corre- 
spond to the previously described protein and cDNA se- 
quences encoding a widely expressed putative helicase 
known as XNP (Gecz et al., 1994) or XH2 (Stayton et al., 
1994), as set out in Figure 3. 
Table 1. ATR-X Syndrome: Two-Point Lod Scores 
Recombination Fraction 
ATR-X versus 0.00 0.01 0.05 0.10 0.20 0.30 0.40 8 Lod~,~x 
DXSI06 -oo 5.36 6.11 5.85 4.61 3.01 1.32 0.052 6.11 
DXS453 -oo 7.68 7.73 7.18 5.60 3.69 1.65 0.027 7.84 
PGK1 9.56 9.40 8.71 7.79 5.79 3.64 1.49 0.000 9.56 
DXS72 -oo 6.93 7.57 7.19 5.70 3.77 1.65 0.045 7.57 
DXYSlX -~ 4.25 5.66 5.66 4.62 3.06 1.33 0.072 5.74 
PGK1 and the dinucleotide tandem repeat sequences PY5-10 and PY2-31 lie on the same 450 kb YAC (Graeber et al., 1992) and were consequently 
treated as a single locus for the purpose of this analysis. Linkage analysis was performed using the LINKAGE program, version 5. Penetrance 
figures used for linkage analysis are given in Gibbons et al. (1992). 
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Figure 2. Characterization f a Deletion i  Patient 26.3 
(a) Genomic DNA (10 gg) from 26 patients and one normal individual 
was digested with Asp-718 and hybridized to the 84 bp cDNA probe 
E4 (representative r sults from four individuals are shown). The sizes 
of the DNA markers are indicated in kilobases on the left. Lanes corre- 
sponding to patient 26.3 and a normal control (N) are indicated. 
(b) Pstl digest probed with 2.5 kb BamHI fragment from cosmid 
ICRFc104A1814 that spans the 26.3 deletion and gives rise to an 
altered band indicated by the arrow in lane 26.3. Two cross-hybridizing 
bands are also present. 
(c) Map of genomic DNA spanning the deletion i 26.3. Abbreviations: 
B, BamHI; P, Pstl. The 2.5 kb BamHI and 4.6 kb Pstl fragments used as 
probes are shown. The location of the cDNA fragment E4 is indicated. 
(d) Northern blot analysis of RNA from ATR-X patients. Poly(A) ÷- 
selected RNA derived from EBV-transformed cell lines (1-2 ~.g) was 
loaded in each lane and hybridized to XNP3/4. Patients 25.1 and 25.2 
are affected maternal cousins; 26.3 and 26.7 are affected maternal 
cousins, both of whom have a deletion of 1973 bp from XH2 as de- 
scribed in the text; patient LO has a similar phenotype to ATR-X but 
without a-thalassemia. Prolonged exposure reveals v ry faint but 
faster-migrating bands in 26.3 and 26.7. 
(e) The Northern blot was hybridized to XNP3/4, identifying a doublet 
migrating at approximately 9.5 kb. Patients 8.1 and 8.2 are affected 
maternal cousins; 10.1 and 10.2 are affected sibs. 
In addition to the clones corresponding to previously 
published sequences (GenBank accession numbers 
L34363 for XNP and U09820 for XH2), we also isolated 
and sequenced cDNAs that extend a further 1.5 kb in the 
3' direction. The cDNA fragment 5.1 (Figure 3) contains 
a putative polyadenylation signal and a poly(A) tail, 14 
nt downstream, confirmed by sequence comparison with 
genomic DNA. From Northern blot analysis (see below), 
we estimate that the XH2 mRNA transcripts are approxi- 
mately 9.5 kb in length; our sequence data (covering 6.5 
kb), combined with the previously published sequence of 
XH2 (Stayton et al., 1994), cover 7605 bp of contiguous 
sequence, suggesting that there is an additional segment 
(2 kb) of uncloned sequence at the 5' end of the cDNA. 
We have not ruled out the possibility of an alternative poly- 
adenylation signal further downstream of the signal that 
we have identified. It is interesting to note that Stayton et 
al. (1994) have placed the initiation codon at position 53 
of the current nucleotide sequence; however, this is some- 
what arbitrary since the open reading frame is maintained 
upstream of this. 
ATR-X Associated with a Partial Deletion of XH2 
Preliminary studies with E4 and XNP3/4 suggested that 
at least part of the XH2 gene had been deleted in patient 
26.3 (see above). Using the small cDNA probe E4, we 
detected no signal in genomic DNA. With the larger 
XNP3/4 cDNA fragment, which includes E4 (see Figure 
3b), both normal-sized and missing genomic fragments, 
corresponding to the missing E4 fragments, were noted. 
To characterize the deletion further, we isolated a cos- 
mid (ICRFc104A1814) from a flow-sorted X chromosome 
library (the Imperial Cancer Research Fund [ICRF] Refer- 
ence Library) using XNP3/4. A 2.5 kb BamHI fragment 
from this cosmid, containing the E4 sequence (see Figure 
2c), identified breakpoint fragments in several different 
digests of genomic DNA from patient 26.3 (e.g., see Figure 
2b). Comparison of the restriction map of normal individu- 
als and 26.3 was consistent with a genomic deletion of 
approximately 2 kb from within the 2.5 kb Bam HI fragment, 
suggesting that the 2.5 kb fragment spans the deletion. 
This fragment was therefore sequenced, and PCR primers 
located close to each BamHI site were designed. When 
DNA from a normal individual was amplified with these 
primers, a 2.5 kb band was identified, whereas when we 
used DNA from 26.3, a 0.5 kb band was seen. Comparison 
of the DNA sequence from the 0.5 kb DNA fragment with 
the normal sequence confirmed that there is a 1973 bp 
genomic deletion from this region (data available on re- 
quest). 
To evaluate the effect of this deletion on expression of 
the XH2 gene, we analyzed RNA derived from EBV- 
transformed lymphoblasts. Using primer XNP3/4, we ob- 
served two closely migrating transcripts of approximately 
9.5 kb in RNA from normal individuals. In the proband 
26.3 and in a similarly affected maternal cousin (26.7), both 
9.5 kb transcripts were missing (see Figure 2d), indicating 
that XH2 is down-regulated by this deletion and also show- 
ing that both transcripts originate from the same locus. 
On prolonged exposure, very faint faster-migrating bands 
were observed. To ensure that XH2 was the only gene 
disrupted by this deletion, a Northern blot was probed with 
a 4.6 kb Pstl genomic fragment spanning the deletion (see 
Figure 2c). Apart from the 9.5 kb doublet previously ob- 
served with XNP3/4, no other transcripts were seen (data 
not shown). 
These findings therefore provide strong evidence that 
the genomic deletion observed in 26.3 causes disruption 
and down-regulation of XH2, a candidate gene for the 
ATR-X syndrome. 
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Figure 3. Characterization of XNP 
(a) Schematic representation of the 7.6 kb 
cDNA characterized for XH2 (large open box). 
The conserved helicase motifs (I-Vl as defined 
by Bork and Koonin, 1993) and the mutations 
in the ATR-X patients are indicated. All num- 
bering is based on a previously published se- 
quence (GenBank accession number U09820). 
(b) The component cDNA clones of the contig 
established in this study are shown (see Experi- 
mental Procedures). Bam2.5 is part of a 2.5 kb 
BamHI genomic fragment (see Figure 2c); PCR 
analysis of genomic DNA and cDNA and se- 
quence analysis revealed that the majority of 
this fragment (1908 bp) is exonic. 
(c) The extent of the cDNA sequences and 
open reading frames previously determined 
(GenBank accession numbers L34363 and 
U09820) is shown. 
(d) The locations of the SSCP primer pairs and 
their products (Table 2) are indicated. 
A Search for Other Mutations of XH2 
in the ATR-X Syndrome 
We did not detect absent or altered bands on Southern 
blot analysis in any of the 25 other ATR-X patients studied, 
However, in view of the findings in 26,3, described above, 
it seemed likely that point mutations or small deletions 
might be presen t in these cases, causing alteration in XH2 
structure or expression. 
To evaluate expression, RNA from EBV-transformed 
lymphoblasts derived from 24 ATR-X patients was exam- 
ined by Northern blot analysis using XNP3/4. RNA was 
detected in all patients studied; however, in some there 
was a marked alteration in the relative intensities of the 
two XH2 transcripts, and the ratio was identically altered 
in other affected members of the same family (e.g., see 
Figure 2e). These findings suggested that mutations in 
these families were causing some perturbation in XH2 
mRNA expression or stability. 
We next analyzed by single strand conformation poly- 
morphism (SSCP) analysis the structure of XH2 cDNA de- 
Table 2. SSCP Primer Pairs 
Primer 
A B 
Annealing 
Product Temperature 
Size (Celsius) 
14 TCATAGTAAAATGACGCTCCACCTG 
16 TGGATGTCATAAGATGGATTCCAAG 
18 TTCCTTGACTGTGCAGTAGTGGAA 
20 GGACTTTATCCCCAATTTCCTCTG 
22 AACATCATTGTCACTGCCACTTCC 
24 ACCTGCCTTTCCTCTTCCACCTTC 
26 TGCACACTGACCATTTTGAATTGG 
28 GCCTTCATCACAAACAACAAATCAG 
30 ACCACCATCTTCTTGCCACCTCTG 
32 AGTATGGTATCCTTTGGCAGCATG 
34 CAGCCCAAGCTGCTTTTCTTTC 
36 TTTGAGAGTTGAAACTGACAGGGG 
38 TCCTGGCTGGCTTGTCTACTTAATC 
40 GCTGCTGGAGCCTTCTGTTCATAAG 
42 TTTTGCTTCTCATTGGGGGTG 
44 CGTGCTGAAATCCAGTTTGTCACAC 
46 ACAGACTCACAGCAGCAATCCCAC 
48 CGGAGCTTAAACTCATGGAGGTTTC 
50 GGAGGAGGAAGATGAAAATGATG 
52 GCCCAGAACAAGGTCTGCAAAG 
54 CAGCATAGGCTTTTCGGCAC 
56 TGGATCTTCAGATGATGAGCCAG 
58 TGGATTTTGCCAATCTTCAGG 
60 AAAGAAGGCAGTCATTGTCAAGG 
62 TCAACACGCATAGAATTGAGGG 
64 GCAAGTTGCTTGAAAGAGTTCATGG 
66 TGATGGCAACTGAAAAGTTACCTG 
68 AAAACGCAGAGCAAAAACGG 
15 TTATATTCGACGCTTCTTGGAATCC 
17 AAAGGTGAGGGGAAGTGGCTTC 
19 GCTGAGGTTTTAGAGCATTCTGGG 
21 TAGCTCAAGTGGAAGTGGCAGTG 
23 GGACTCATCCTTGGTGTTTGCAG 
25 CCAATTCAAAATGGTCAGTGTGCAG 
27 TGCTCAAGGAAGGAATGTGAAGAG 
29 ACGTCCTCAGGAGAGAAGCTACATG 
31 TGCATTCTTGCCCACTGTATGG 
33 TCGGCAAGTAACTAAGCAGTCACTG 
35 GCAGGTGGAGCGTCATTTTACTATG 
37 GCCAAAGGATACCATACTTGCAGAG 
39 CGTTTCAACATACCAACTGGGACC 
41 GCAGTGAGGATTCAACCTCTTGAGG 
43 AGGCTCCAGCAGCAGTACAATCAG 
45 CACCCACCAAGTGTCCAATAACAAC 
47 CGGAAGATTCTTAAAGATGATAAA 
49 TGTGGGCAATAATAGTGAAGGTGG 
51 ACACTTGGTGGGTGAAGCATC 
53 TGCCTTTTCCAGGAGACTTGG 
55 TTCCAACTCTGCTTTCTTTGCAG 
57 AGATTCTCCGAAACTCAAAAGCC 
59 TTTGCTTCCTCATCTCCTGGG 
61 TTGTCGTCATCATCATCATCCAC 
63 TGAGGATGTAATGTCAGCTTGCTTC 
65 TCTCCTTGACAATGACTGCCTTC 
67 CGTGTCTCTTCCATGAACTCTTTC 
69 TCCCTGTTGACTTCTCAGCATAATC 
201 52.9 
224 52.1 
257 53.4 
290 53.8 
204 52 
261 53.2 
302 51.8 
182 53.3 
264 54.6 
180 52.8 
251 53.5 
224 53.7 
281 56.6 
220 54.6 
211 55.1 
284 54.1 
295 59 
201 52.6 
211 52.6 
227 53.7 
231 53.1 
187 51.7 
234 52.2 
270 52.6 
225 51.1 
270 52 
277 51.2 
268 50.5 
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Figure 4. Mutation Analysis in Patients with ATR-X 
(a) SSCP analysis of a panel of ATR-X patients and a normal individual 
(N), utilizing the primer pair XNP30/31. Altered bands were noted in 
pedigrees 14, 5, and 21 and were subjected to sequence analysis. 
(b) Sequence analysis of the sense strand from pedigrees 14 and 5 
showing an A to G transition at nucleotide 2302 and a T to C transition 
at nucleotide 2316, respectively. 
rived from EBV-transformed lymphoblasts from 24 ATR-X 
patients, using primers designed to generate overlapping 
150-300 bp fragments (Figure 3d; Table 2). In this way, 
4.5 kb of the 9.5 kb mRNA transcript, including most of 
the currently known coding sequence, was analyzed. In 
addition, amplified fragments generated from primers 7 
and 8, which contain an imperfect trinucleotide repeat 
(Gecz et al., 1994), were examined and found to be of normal 
size in 24 patients. By SSCP analysis we detected 11 al- 
tered bands corresponding to cDNA fragments from nine 
unrelated pedigrees. In two cases, SSCP changes were 
present in adjacent fragments where a mutation occurred 
in the region of overlap between PCR fragments (Table 3). 
Variant SSCP fragments were amplified and sequenced, 
revealing nine different mutations (Figure 4; Table 3); in 
one case, the same mutation was seen in two similarly 
affected individuals from the same family (21.1 and 21.2). 
In pedigrees 13 and 14, fetuses with the "affected" haplo- 
type were found to have the same mutation as the affected 
proband. The locations of these mutations in XH2 are 
shown in Figure 3a. Two (C4635T and G4641T) give rise 
to premature in-phase stop codons. The remainder are 
missense mutations that fall in the central portion of the 
molecule, a region that is known to be highly conserved 
among members of the superfamily of DNA helicases to 
which XH2 belongs (Bork and Koonin, 1993). Although the 
mutations did not fall precisely into the previously pro- 
posed motifs (I-VI), based on protein sequence alignment, 
with one exception (N1002S), they occurred in areas that 
are well conserved among members of the helicase super- 
family (Figure 5). It is interesting that none of the mutations 
involves a highly convserved amino acid, which may mean 
that such mutations are lethal. Given the relatively conser- 
vative amino acid change in N 1002S and its nonconserved 
location, we cannot be certain that this is the disease- 
causing mutation i family 20. However, the nature of the 
other eight mutations identified here, their occurrence in 
similarly affected individuals from the same family, and 
their locations in highly conserved regions of XH2 suggest 
that they cause significant disruption of its structure and 
function, thereby leading to the ATR-X phenotype. 
Discussion 
We have shown that the ATR-X syndrome results from 
mutations involving XH2, a gene that lies in the region 
Xq13.3. A wid e variety of mutations distributed throughout 
the central portion of the XH2 protein give rise to a surpris- 
ingly uniform phenotype that includes severe psychomo- 
tor retardation, a similar pattern of facial dysmorphism, 
and a-thalassemia. Consistent with the complex ATR-X 
phenotype, studies of XH2 and its murine homolog Mxnp 
(Gecz et al., 1994; Stayton et al., 1994; unpublished ata) 
Table 3. Summary of ATR-X Mutations Identified by SSCP Analysis 
Pedigree Number SSCP Primer Pair cDNA Nucleotide Change Amino Acid Change Restriction E zyme Site 
14 (1, 2) 30131,44•45 A2302G H750R Creates Rsal 
5 30131 T2316C C755R 
21 (1, 2) 30131 G2429T K792N Disrupts Hindlll 
20 24125 A3058G N 1002S 
23 18119 A3583T D1177V Creates Msel 
3 16/17, 18/19 T3729C Y1226H Creates Hphl 
13 (1, 2) 14/15 A3967G Y1305C 
16 40/41 C4635T R1528* 
27 40/41 G4641T E1530" Disrupts Earl 
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Figure 5. Location of Six ATR-X Mutations in Relation to Conserved 
Domains 
Sequence alignment of various members of the helicase superfamily 
(indicated on the left). The locations of six mutations identified in ATR-X 
patients (arrows) are shown in relation to conserved regions both within 
and outside the helicase domains (overlined). The N1002S missense 
mutation that occurs in a nonconserved region is not shown. The amino 
acids are divided into blocks of ten, with the residue number for each 
family member given on the right. 
have shown it to be a widely expressed gene that might 
play an important role in development of the central ner- 
vous system. At present, the role of XH2 in development 
of the urogenital system is not known but, since 96% of 
ATR-X patients also have genital abnormalities (Gibbons 
et al., 1995), it seems likely that XH2 will also be involved in 
this pathway. The most extreme urogenital abnormalities, 
causing severe hypogenitalism, male pseudohermaphro- 
ditism, and in some cases female gender assignment, 
were caused by a partial deletion of XH2, premature in- 
phase stop codons (R1528" and E1530 *), and a missense 
mutation (C755R). We have previously shown that severe 
genital abnormalities appear to "breed true" with the dis- 
ease (McPherson et al., 1995; Reardon et al., 1995). It will 
therefore be interesting to see whether specific types of 
mutation, perhaps those producing no XH2 protein, are 
associated with this particular phenotype. 
Previous studies have shown that XH2 is subject to X 
inactivation and is exclusively transcribed from the active 
X chromosome (Stayton et al., 1994). Female carriers of 
ATR-X have a markedly skewed pattern of X inactivation 
in all tissues that have been studied, and we previously 
considered whether this might be due to selection against 
the affected chromosome or to the direct involvement of 
the X inactivation center, which lies close to the ATR-X 
locus (X/ST in Figure 1). In the absence of any large chro- 
mosomal rearrangements involving both the X inactivation 
center and XH2 loci, selection seems the most likely expla- 
nation. If selection accounts for the skewed pattern of X 
inactivation seen in female carriers, this suggests that un- 
less mutations in XH2 are independently selected against 
in each tissue, XH2 must be expressed prior to differentia- 
tion of the embryonic endoderm, ectoderm, and meso- 
derm in humans. It is therefore of interest that Mxnp is 
already expressed in the primitive streak at the earliest 
stage of mouse development (7.0 days postcoitum) that 
has yet been studied (Stayton et al., 1994). 
Sequence analysis has shown that XH2 belongs to the 
SNF2 subgroup (Kolst~ et al., 1993) of a superfamily of 
proteins with similar DNA-dependent ATPase (I and II in 
Figure 3a) and proven or putative DNA helicase ( I I I -V I  
in Figure 3a) domains (Bork and Koonin, 1993). Regions 
outside the helicase domains also show considerable con- 
servation among members of this SNF2 subgroup (Matson 
et al., 1994). These proteins are involved in a wide variety 
of cellular functions, including mitotic chromosome segre- 
gation (lodestar), DNA recombination and repair (RAD16, 
RAD64, and ERCC6), and global regulation of transcrip- 
tion (SWl2/SNF2, MOT1, brahma) (reviewed by Carlson 
and Laurent, 1994). Using comparative analysis, we found 
no additional protein motifs associated with particular sub- 
groups of the SNF2 family (e.g., bromodomains [Haynes 
et al., 1992], chromodomains [Delmas et al., 1993], DNA- 
binding or activation motifs [Stayton et al., 1994], kinases 
[Tsuchiya et al., 1992], and TPR boxes [Davis et al., 1992]). 
Furthermore, recent evidence has shown that although 
some proteins in this superfamily are predominantly in- 
volved with either repair (e.g., RAD16) or transcriptional 
control (e.g., SWl2/SNF2), the two processes are closely 
connected (Drapkin et al., 1994). Therefore, at present, the 
best guide to the normal function of XH2 comes from an 
evaluation of the phenotypic effects of mutation. In contrast 
with other human genetic diseases (xerodema pigmento- 
sum [Hoeijmakers, 1993], trichothiodystrophy [Broughton 
et al., 1994], and Cockayne's syndrome [Troelstra et al., 
1992]) that result from mutations in genes of the helicase 
superfamily, in the ATR-X syndrome there is no clinical 
evidence for ultraviolet sensitivity or the premature devel- 
opment of malignancy. Furthermore, cytogenetic analysis 
has not demonstrated any evidence of abnormal chromo- 
some breakage or segregation. However, the consistent 
association of ATR-X, due to a wide range of independent 
mutations, with down-regulation of a-gtobin expression 
suggests that XH2 is involved in the regulation of gene 
expression. 
Mutations of XH2 might affect any stage of gene expres- 
sion, but the SNF2 family to which it belongs is distinct from 
the group of DEAD box RNA helicases, some members of 
which have been implicated in RNA processing, stability, 
or translation (Pain, 1986; Strauss and Guthrie, 1991 ; lost 
and Dreyfus, 1994). From a functional point of view, pertur- 
bation of XH2 appears to resemble most closely the effects 
that would be expected from disruption of a global tran- 
scriptional regulator, the best-studied examples being 
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brahma in Drosophila (Tamkun et al., 1992) and the SNF/ 
SWl family in Saccharomyces cerevisiae (Winston and 
Carlson, 1992). Although the precise mechanism by which 
these proteins exert their effect is not known, they appear 
to regulate transcription of restricted classes of genes via 
interactions with gene-specific activators, most likely by 
altering chromatin structure to relieve repression (Carlson 
and Laurent, 1994). In this respect, it is most interesting 
that mutations in XH2 down-regulate expression of the 
(~-globin genes but do not appear to affect the closely re- 
lated I~-globin genes. Activation of the (~- and I~-globin 
genes appears to involve a common group of lineage- 
specific (GATA-1 and NF-E2) and ubiquitous (CACC box) 
DNA-binding proteins. However, despite their common an- 
cestry, human a- and I~-globin clusters have been pre- 
viously shown to lie in remarkably different chromosomal 
environments (reviewed by Vyas et al., 1992). The a genes 
are associated with CpG-rich islands located in a constitu- 
t ively "open," transcriptionally active chromatin domain 
that is early replicating in all cell types, and their expres- 
sion is regulated by a remote tissue-specific enhancer. By 
contrast, the 13 cluster is contained within a segment of 
chromatin that opens and becomes early replicating in a 
tissue-specific manner under the influence of a remote 
locus control region (Grosveld et al., 1987; Forrester et 
al., 1990). In addition, unlike the ~ cluster, the 13 cluster 
contains several matrix attachment regions (Jarman and 
Higgs, 1988) that may act as histone H1 nucleation sites 
(Zhao et al., 1993) and thereby influence long-range chro- 
matin structure. The specific effect of XH2 mutations on 
(z- rather than 13-globin expression may therefore indicate 
that XH2 is a transcriptional activator that, like other similar 
proteins (e.g., SNF/SWl and brahma), works via an inter- 
action with chromatin. It is interesting to note that all the 
diverse mutations of XH2, including a deletion that se- 
verely reduces the level of XH2 mRNA, cause (z-thalas- 
semia, implying that rather th an the (z genes being affected 
as "innocent bystanders" in these mutations, XH2 is nor- 
mally necessary for their correct regulation. Further analy- 
sis of the role of XH2 in the control of gene expression is 
therefore likely to elucidate the normal mechanisms of 
(~-globin regulation. 
It is of interest that many forms of XLMR and complex 
human genetic disorders map to Xq13-q21 (Schlessinger 
et al., 1993). Although the patients that we have studied 
have been highly selected for a specific phenotype, they 
have mutations distributed throughout the XH2 gene. Al- 
though this might suggest that any perturbation of XH2 
expression will cause ATR-X, mutations should be sought 
in other forms of XLMR that map to this region. We have 
identified several pedigrees in which affected individuals 
have a phenotype very similar to ATR-X but in whom we 
cannot detect hemoglobin H inclusions; these include a 
pedigree with the Juburg-Marsidi  syndrome (Saugier- 
Veber et al., 1995). Analysis of XH2 in all of these families 
is currently underway. 
Experimental Procedures 
DNA/RNA Sources and Analysis 
EBV-transformed lymphoblastoid patient cell lines (Gibbons et al., 
1995) were used as a source of both genomic DNA and RNA. cDNA 
was prepared from cell line RNA by RT-PCR as described by Brown 
et al. (1990). YAC4551 (provided by Dr. A. Monaco, ICRF, Oxford, 
England) was used for mapping back cDNA probes. Cosmids covering 
the 3' end of the XH2 gene were obtained by screening the X chromo- 
some flow-sorted ICRF Reference Cosmid Library (Lehrach et al., 
1990) with probe XNP3/4. The 2.5 kb BamHI and the 4.6 kb Pstl frag- 
ments from cosmid ICRFc104A1814 were subcloned into pBluescript 
I1. Northern and Southern blots were performed as described in Sam- 
brook et al. (1989). Final washing conditions were performed at either 
room temperature or at 65°C in 0.1 x SSC and 0.1% SDS for 5 min. 
cDNA Isolation and Characterization 
Initially, a human fetal brain library in ~, phage (from Dr. P. C. Harris, 
Institute of Molecular Medicine, Oxford, England) was screened with 
E4. One cDNA was isolated that contained two EcoRI fragments (1.88 
and 0.56) that were cloned into pBluescript II for further analysis. Three 
additional cDNAs (P12, P16, and data not shown) were isolated from 
this library after screening with the 0.56 fragment. Five additional 
cDNA fragments (hh4, 5.1, 5.2, 6.2, and data not shown) were isolated 
from a human heart Z phage cDNA library (Stratagene Cloning Sys- 
tems) or from a human fetal brain plasmid cDNA library (from Dr. D. J. 
Blake, Institute of Molecular Medicine, Oxford, England) prepared in 
the vector pcDNAII (Invitrogen Corporation), probing with either 
XNP3R/SR, the BamHI 2.5 kb genomic fragment, or the 2.1 kb BamHI- 
Pstl genomic fragment (Figure 2c). cDNA fragments XNP3/4 and 
XNP3P,/8R were amplified from cDNA from a normal individual and 
cloned into pUC18 at the Smal site. 
DNA Sequence Analysis 
Double-stranded sequencing of genomic or cloned cDNA fragments 
(Chen and Seeburg, 1985) was performed with Sequenase T7 polymer- 
ase (United States Biochemicals) using sequential truncations (Heni- 
koff, 1984) or selected oligonucleotide primers (see Table 2). ATR-X 
patients showing an altered SSCP band and normal control samples 
were directly sequenced after PCR amplification as described in Thein 
and Hinton (1991). 
PCR Amplification and SSCP Analysis 
XNP3/4 and XNP7/8 were amplified from cDNA derived from a normal 
EBV-transformed lymphoblastoid line utilizing primers XNP3, XNP4, 
XNP7, and XNP8 using previously described conditions (Gecz et al., 
1994). Similarly, XNP3FESR was amplified using primers XNP3R and 
XNP8R, the reverse complements of XNP3 and XNPS, respectively. 
To characterize the 26.3 breakpoint, we employed primers Bam2.5f 
(5'-GATCCACCAAACCTCACAAATTCTG-3') and Bam2.5r (5"GCCA- 
GCCI-I-CTGCCTTATACI-rG-3'). Cycles were as follows: once at 94°C 
for 5 rain, at 52.7°C for 1 min, and at 72°C for 2.5 min; 28 times at 
94°C for 1 rain, at 52.7°C for 1 min, and at 72°C for 2.5 rain; once 
at 94°C for 1 rain, at 52.7°C for 1 min, and at 72°C for 10 rain. Typically, 
all PCRs were performed in PCR buffer (50 mM KCI,10 mM Tris-HCI 
[pH 8.8]. 0.01% gelatin) containing 0.5-2.0 mM MgCI2, 200 p.M dNTPs, 
0.5 I~M of each primer, 2.5 U/100 I11AmpliTaq (Perkin-Elmer Cetus), 
100 ng of genomic DNA or 1 p.I of cDNA prepared as described above, 
in a final volume of 50 p.I. For SSCP analysis, PCRs were performed 
in 10 p,I with 1 I~1 of a 5-fold dilution of cDNA template and the addition 
of 0.1 Id of [(x-32P]dCTP (3000 Ci/mmol; Amersham). Annealing temper- 
ature was adjusted for each primer pair (Table 2). Cycles were as 
follows: once at 94°C for 5 min, annealing for 1 min, and then at 72°C 
for 1 min; 28 times at 94°C 1 for min, annealing for 1 min, and then 
at 72°C for 1 rain; once at 94°C for 1 min, annealing for 1 min, and then 
at 72°C for 4 min. Analysis of labeled SSCP products was performed 
according to the method of Glavac and Dean (1993). 
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